Global miRNA Sequencing and Assay Market, By Product (Sequencing Consumables, Library Preparation Kits), Technology (Sequencing by Synthesis, Ion Semiconductor, Solid, Nanopore Sequencing), End-User (Clinical Laboratory, Life Science Organization, Other End-Users) – Industry Trends and Forecast to 2031.
miRNA Sequencing and Assay Market Analysis and Size
The growing application of miRNA sequencing in the medical field is driving the market. Numerous studies have demonstrated the use of miRNAs as biomarkers in the diagnosis and prognosis of sepsis, cardiac disorders, nervous system disorders, and malignancies (breast, ovarian, and cervical). Because of this, miRNA sequence analysis is frequently employed to examine the regulation of genes in clinical disorders. For example, a March 2023 molecular neuroscience paper published in Frontiers suggested that it might be able to link blood-based miRNA indicators with brain-based miRNA expression.
Data Bridge Market Research analyzes that the global miRNA sequencing and assay market, which was USD 381.39 million in 2023, is likely to reach 916.55 million by 2031 and is expected to undergo a CAGR of 11.6% during the forecast period. “Hospitals" dominate the end segment of the miRNA sequencing and assay market due to increasing awareness of proper medication. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Sequencing Consumables, Library Preparation Kits), Technology (Sequencing by Synthesis, Ion Semiconductor, Solid, Nanopore Sequencing), End-User (Clinical Laboratory, Life Science Organization, Other End-Users)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Spain, Turkey, U.K., Netherlands, Russia, Switzerland, Belgium, Hungary, Italy, Rest of Europe, China, India, Japan, Australia, South Korea, Malaysia, Singapore, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Thermo Fisher Scientific, Inc., (U.S.), Illumina, Inc., (U.S.), QIAGEN, (Netherlands), PerkinElmer, Inc., (U.S.), Abcam plc, (U.K.), New England Biolabs, (U.S.), Takara Bio Inc., (Japan), Lexogen GmbH, (Austria), Norgen Biotek Corp., (Canada), Maravai LifeSciences, (U.S.), HTG Molecular Diagnostics, Inc., (U.S.), Meridian Bioscience, Inc., (U.S.), System Biosciences, LLC., (U.S.)
|
|
Market Opportunities
|
|
Market Definition
MiRNA (MicroRNA) sequencing and assay refer to the processes and technologies used to analyze and quantify microRNAs. MicroRNAs are short RNA molecules that play a crucial role in the regulation of gene expression. Understanding the expression patterns and functions of microRNAs is essential in various biological and medical research areas.
Global MiRNA Sequencing and Assay Market Dynamics
Drivers
- Increasing research in functional genomics
The escalating focus on functional genomics, the study of gene function and regulation, propels the demand for miRNA sequencing. Researchers aim to unravel the intricate roles miRNAs play in gene regulation, contributing to a deeper understanding of cellular processes and disease mechanisms.
- Rising incidence of chronic diseases
Chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions involve miRNA dysregulation. The growing prevalence of these diseases heightens the urgency for advanced diagnostic tools, fostering the adoption of miRNA sequencing to identify biomarkers for early detection and targeted therapies.
- Advancements in next-generation sequencing (NGS) technologies
The continual evolution of NGS technologies empowers miRNA sequencing by enhancing accuracy, speeding up the sequencing process, and reducing costs. These advancements make miRNA analysis more accessible and facilitate comprehensive profiling of miRNA expression patterns.
Opportunities
- Emerging applications in disease biomarkers
The identification of miRNA biomarkers holds promise for revolutionizing disease diagnostics and prognostics. As researchers uncover specific miRNA signatures associated with various diseases, the opportunities for developing targeted and minimally invasive diagnostic tools expand.
- Technological innovations
Ongoing innovations in miRNA sequencing and assay technologies, such as the development of user-friendly platforms and integrated analysis solutions, present opportunities for market expansion. Enhanced ease of use and accessibility can encourage broader adoption across diverse research settings.
- Collaborations and partnerships
Collaborations between biotechnology firms, research institutions, and pharmaceutical companies foster a synergistic environment for advancing miRNA research. Shared expertise and resources accelerate the development of novel applications and technologies, propelling market growth.
Challenges/Restraints
- High cost of sequencing technologies
The initial investment required for miRNA sequencing technologies can be prohibitive for smaller research entities and laboratories. This financial barrier may limit the widespread adoption of miRNA analysis, especially in resource-constrained settings.
- Limited awareness and expertise
Despite the increasing significance of miRNA analysis, there is a gap in awareness and expertise among healthcare professionals and researchers. Limited knowledge about the applications and interpretation of miRNA data may impede its incorporation into mainstream research and diagnostics.
Recent Development
- In April 2022, HTC Molecular Diagnostics Inc. unveiled new features of its proprietary HTG EdgeSeq technology. The company has improved its technology, and now its new sample preparation harmonization enables miRNA and mRNA profiling without the need for additional samples
- In January 2022, Allogene Therapeutics announced a collaboration with Antion Biosciences to advance multiplex gene silencing for the development of next-generation allogeneic CAR T products. As part of the collaboration, Antion's miRNA technology (miCAR) will be used as an additional tool to enhance the efficacy and safety of allogeneic CAR T therapies
Global MiRNA Sequencing and Assay Market Scope
The miRNA sequencing and assay market is segmented on the basis of product, technology, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Sequencing Consumables
- Library Preparation Kits
Technology
- Sequencing by Synthesis
- Ion Semiconductor
- Solid
- Nanopore Sequencing
End-User
- Clinical Laboratory
- Life Science Organization
- Other End-Users
Global MiRNA Sequencing and Assay Market Regional Analysis/Insights
The miRNA sequencing and assay market is analyzed and market size insights and trends are provided by country, product, technology, and end-users as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market because of the growing geriatric population and over use of unhealthy food in this region. In addition, the surging number of initiatives taken by the pharmaceutical organizations to generate novel formulation mainly for paediatric population and rising healthcare expenditure will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to surging government initiatives to spread awareness and increasing the geriatric population in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The miRNA sequencing and assay market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for miRNA sequencing and assay market , impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on miRNA sequencing and assay market. The data is available for historic period 2010-2020.
Competitive Landscape and Global MiRNA Sequencing and Assay Market Share Analysis
The miRNA sequencing and assay market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to miRNA sequencing and assay market .
Some of the major players operating in the miRNA sequencing and assay market are:
- Thermo Fisher Scientific, Inc., (U.S.)
- Illumina, Inc., (U.S.)
- QIAGEN, (Netherlands)
- PerkinElmer, Inc., (U.S.)
- Abcam plc, (U.K.)
- New England Biolabs, (U.S.)
- Takara Bio Inc., (Japan)
- Lexogen GmbH, (Austria)
- Norgen Biotek Corp., (Canada)
- Maravai LifeSciences, (U.S.)
- HTG Molecular Diagnostics, Inc., (U.S.)
- Meridian Bioscience, Inc., (U.S.)
- System Biosciences, LLC., (U.S.)
SKU-